Image-guided breast tumor therapy using a small interfering RNA nanodrug

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Iron oxide nanoparticles are explored for combined tumor imaging and small interfering RNA (siRNA) delivery.
• Targeted delivery of therapeutic agents to tumors remains a significant challenge in cancer treatment.

Purpose of the Study:

• To synthesize and evaluate a novel tumor-targeted nanodrug (MN-EPPT-siBIRC5) for simultaneous imaging and siRNA delivery to human breast tumors.
• To assess the efficacy of the nanodrug in targeting the uMUC-1 antigen, downregulating the BIRC5 gene, and inhibiting tumor growth in preclinical models.

Main Methods:

• Synthesis of MN-EPPT-siBIRC5 comprising superparamagnetic iron oxide nanoparticles, Cy 5.5 dye, uMUC-1 targeting peptides, and BIRC5-targeting siRNA.
• In vitro studies involving human breast adenocarcinoma cells to assess nanodrug uptake and BIRC5 gene downregulation.
• In vivo studies using subcutaneous mouse models of breast cancer to evaluate tumor targeting, imaging (MRI and near-IR optical), and therapeutic efficacy after intravenous administration.

Main Results:

• Nanodrug uptake by cancer cells led to significant downregulation of the BIRC5 gene.
• In vivo studies demonstrated preferential tumor accumulation of the nanodrug, visualized by MRI and near-IR optical imaging.
• MRI enabled quantitative monitoring of nanodrug bioavailability in tumors.
• Treatment resulted in significant tumor necrosis, apoptosis, and a decreased tumor growth rate.

Conclusions:

• The developed nanodrug (MN-EPPT-siBIRC5) enables simultaneous, tumor-specific delivery of siRNA and imaging of the delivery process.
• This approach shows potential for application in various human cancer studies, including basic tumor biology and therapy.
• The combination of imaging and therapeutic delivery via targeted nanoparticles offers a promising strategy for cancer treatment.